INNO 201
Latest Information Update: 27 Nov 2007
At a glance
- Originator Innogenetics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pulmonary oedema
Most Recent Events
- 28 Jun 2004 INNO 201 is available for partnering (http://www.innogenetics.com)
- 31 Dec 2001 Preclinical trials in Pulmonary oedema in Europe (unspecified route)